5-乙氧基吲哚 | 10501-17-4

• 物质功能分类: 医药中间体 - 吲哚类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-乙氧基吲哚
• 英文名称: 5-ethoxyindole
• 英文别名: 5-ethoxy-1H-indole；5-Ethoxy-indol
• CAS: 10501-17-4
• 化学式: C₁₀H₁₁NO
• 分子量: 161.203
• InChiKey: IEKPDICCMASELW-UHFFFAOYSA-N

物化性质

• 熔点：
  35-36 °C
• 沸点：
  192 °C(Press: 11 Torr)
• 密度：
  1.132±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  25
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8℃，惰性气体

反应信息

• 作为反应物：
  描述：

  5-乙氧基吲哚 在 盐酸 、 三氯氧磷 作用下， 以 甲醇 为溶剂， 反应 6.75h， 生成 1-[(E)-(5-ethoxy-1H-indol-3-yl)methylideneamino]-2-pentylguanidine
  参考文献：
  名称：

  The Serotonin 5-HT4 Receptor. 2. Structure-Activity Studies of the Indole Carbazimidamide Class of Agonists

  摘要：

  A number of substituted indole carbazimidamides were prepared and evaluated as 5-HT4 receptor agonists by using the isolated field-stimulated guinea pig ileum preparation. Their selectivity for the 5-HT4 receptor was established by examining their affinity for other 5-HT receptors using radioligand-binding techniques. Several selective and highly potent full as well as partial agonists emerged from this study. For example, 1b,d were found to be the most potent, full 5-HT4 receptor agonists described so far (EC(50) = 0.5 and 0.8 nM, respectively), being 6 and 4 times more potent than serotonin itself. On the other hand, 5b and 1h appeared as partial 5-HT4 receptor agonists in the nonstimulated guinea pig ileum preparation with potencies, evaluated against serotonin action, respectively similar (5b, K-i = 12 nM) to and 300-fold higher (1h, K-i = 0.04 nM) than serotonin.

  DOI：

  10.1021/jm00013a010
• 作为产物：
  描述：

  5-ethoxy-indole-2-carboxylic acid 生成 5-乙氧基吲哚
  参考文献：
  名称：

  543. Bz取代的吲哚和色氨酸合成的实验。第二部分 尝试合成Bz-硝基吲哚和-色氨酸。5-乙氧基色氨酸和4：5-和6：7-苯并色氨酸的合成

  摘要：

  DOI：

  10.1039/jr9510002462

文献信息

• New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation
  作者：Antonio Coluccia、Sara Passacantilli、Valeria Famiglini、Manuela Sabatino、Alexandros Patsilinakos、Rino Ragno、Carmela Mazzoccoli、Lorenza Sisinni、Alato Okuno、Osamu Takikawa、Romano Silvestri、Giuseppe La Regina

  DOI：10.1021/acs.jmedchem.6b00718

  日期：2016.11.10

  Indoleamine 2,3-dioxygenase 1 (IDO1) is an attractive target for anticancer therapy. Herein, we report a virtual screening study which led to the identification of compound 5 as a new IDO1 inhibitor. In order to improve the biological activity of the identified hit, arylthioindoles 6–30 were synthesized and tested. Among these, derivative 21 exhibited an IC50 value of 7 μM, being the most active compound

  吲哚胺 2,3-双加氧酶 1 (IDO1) 是抗癌治疗的一个有吸引力的目标。在此，我们报告了一项虚拟筛选研究，该研究导致将化合物5鉴定为新的 IDO1 抑制剂。为了提高所识别命中的生物活性，arylthioindoles 6 - 30合成并测试。其中，衍生物21的IC 50值为7 μM，是该系列中活性最强的化合物。此外，化合物5和21诱导表达 IDO1 的癌细胞系 HTC116 和 HT29 的剂量依赖性生长抑制。为了使获得的结果合理化并提出新的化学修饰，进行了三维定量构效关系研究。
• [EN] MTHFD2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE MTHFD2 ET UTILISATION DESDITS INHIBITEURS
  申请人：RAZE THERAPEUTICS INC

  公开号：WO2017023894A1

  公开（公告）日：2017-02-09

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用它们的方法。
• Erythropoietin Expression Promoter
  申请人：TOHOKU UNIVERSITY

  公开号：US20150353489A1

  公开（公告）日：2015-12-10

  The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R 3 is OH.

  本发明提供了一种促进红细胞生成素表达的药剂，可以取消红细胞生成素产生的抑制或促进红细胞生成素的产生，并且包括用于贫血的治疗或预防药物、改善肝功能的药剂、改善缺血性损伤的药剂、肾脏保护剂和胰岛素分泌促进剂，其中包括红细胞生成素表达增强剂。本发明的红细胞生成素表达增强剂包括从以下一般式（I）、（II）和（III）所代表的化合物组中选择的一个或多个化合物及其在R3为OH时的药用盐。
• Palladium-catalyzed regioselective C–H alkynylation of indoles with haloalkynes: access to functionalized 7-alkynylindoles
  作者：Songjia Fang、Guangbin Jiang、Meng Li、Zhenying Liu、Huanfeng Jiang、Wanqing Wu

  DOI：10.1039/c9cc07263b

  日期：——

  A palladium-catalyzed uniquely regioselective C–H alkynylation of indoles has been described. In this protocol, simple and readily available haloalkynes are employed as efficient alkynylating reagents, affording a series of functionalized 7-alkynylindoles in moderate to good yields. Moreover, further transformations of 7-alkynylated products were performed, which demonstrated the potential application

  已经描述了钯催化吲哚的唯一区域选择性C–H炔基化反应。在该方案中，简单易用的卤代炔烃被用作有效的炔基化试剂，以中等至良好的收率提供了一系列功能化的7-炔基吲哚。此外，进行了7-炔基化产物的进一步转化，证明了该方法在有机合成中的潜在应用。
• [EN] INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5 )<br/>[FR] INDOLOPYRIDINES EN TANT QU'INHIBITEURS DE LA PROTÉINE DE FUSEAU KINÉSINE (EG5)
  申请人：4SC AG

  公开号：WO2009024190A1

  公开（公告）日：2009-02-26

  Compounds of formula (I), in which R1, R2, R3 and R4 have the meanings indicated in the description, are effective Eg5-inhibiting compounds with anti-proliferative and/or apoptosis inducing activity.

  式（I）中的化合物，其中R1、R2、R3和R4具有描述中指示的含义，是具有抗增殖和/或诱导凋亡活性的有效Eg5抑制化合物。